AURA
Aura Biosciences IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$428.52M
P/E Ratio
—
EPS
$-1.76
Beta
0.35
52W High
$7.48
52W Low
$4.34
50-Day MA
$5.94
200-Day MA
$6.09
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Aura Biosciences Inc
Aura Biosciences Inc is a pioneering clinical-stage biotechnology company focused on transforming cancer treatment through its proprietary virus-like particle (VLP) technology. Its lead candidate, AU-011, is designed to selectively target ocular cancers, enabling the targeted destruction of tumor cells while protecting surrounding healthy tissue. With a robust clinical pipeline aimed at addressing significant unmet needs in oncology, Aura is backed by an experienced management team and strategic partnerships. The company's commitment to innovation and thorough clinical evaluation positions it for significant impact in the area of targeted cancer therapies, catering to a rapidly evolving market landscape.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-111.66M |
| Operating Margin | 0.00% |
| Return on Equity | -73.50% |
| Return on Assets | -40.10% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $2.15 |
| Price-to-Book | 3.06 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -5.68 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $64.15M |
| Float | $37.11M |
| % Insiders | 2.43% |
| % Institutions | 84.60% |
Analyst Ratings
Consensus ($20.00 target)
1
Strong Buy5
BuyData last updated: 4/7/2026